Bicycle Therapeutics PLC (BCYC) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on October 1, 2024, the Compensation Committee of the company’s Board of Directors...

Form 8-K - Current report

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall...

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on September 3, 2024, the Compensation Committee of the company’s Board of...

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its...

Form S-8 - Securities to be offered to employees in employee benefit plans